Undifferentiated connective tissue disease-associated interstitial lung disease: Changes in lung function

Lung

Volumn 188, Issue 2, 2010, Pages 143-149

  Kinder, Brent W ^a,b   Shariat, Cyrus ^c   Collard, Harold R ^d   Koth, Laura L ^d   Wolters, Paul J ^d   Golden, Jeffrey A ^d   Panos, Ralph J ^a,b   King Jr , Talmadge E ^d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune disease; Collagen vascular disease; Idiopathic interstitial pneumonia; Systemic rheumatic disease; Undifferentiated connective tissue

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONFOUNDING VARIABLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LONGITUDINAL STUDY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE;

ADULT; CHI-SQUARE DISTRIBUTION; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LOGISTIC MODELS; LONGITUDINAL STUDIES; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; ODDS RATIO; PULMONARY DIFFUSING CAPACITY; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 77949875541     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-009-9226-7     Document Type: Article

References (30)

1. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81(2):139-153
2. Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR et al (2001) Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164(7):1182-1185
3. Kocheril SV, Appleton BE, Somers EC, Kazerooni EA, Flaherty KR, Martinez FJ et al (2005) Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 53(4):549-557
4. Hubbard R, Venn A (2002) The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 41(6):676-679
5. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG et al (2007) Prognosis of fibrotic interstitial pneumonia: idio-pathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 175(7):705-711
6. Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M et al (2003) Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 21(3):313-320
7. Williams HJ, Alarcon GS, Joks R, Steen VD, Bulpitt K, Clegg DO et al (1999) Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 26(4):816-825
8. Danieli MG, Fraticelli P, Salvi A, Gabrielli A, Danieli G (1998) Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol 17(3):195-201
9. Mosca M, Tavoni A, Neri R, Bencivelli W, Bombardieri S (1998) Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year. Lupus 7(2):95-100
10. Clegg DO, Williams HJ, Singer JZ, Steen VD, Schlegel S, Zi-minski C et al (1991) Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 18(9):1340-1343
11. Mosca M, Tani C, Neri C, Baldini C, Bombardieri S (2006) Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev 6(1):1-4
12. Mosca M, Neri R, Bombardieri S (1999) Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheu-matol 17(5):615-620
13. Doria A, Mosca M, Gambari PF, Bombardieri S (2005) Defining unclassifiable connective tissue diseases: incomplete, undiffer-entiated, or both? J Rheumatol 32(2):213-215
14. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B et al (2007) Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 176(7):691-697
15. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR et al (1998) Prognostic significance of histopath-ologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157:199-203
16. Nicholson AG, Colby TV, Dubois RM, Hansell DM, Wells AU (2000) The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162:2213-2217
17. American Thoracic Society/European Respiratory Society (2002) International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277-304
18. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG et al (2003) Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167(7):962-969
19. King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G et al (2005) Analyses of efficacy end points in a controlled trial of interferon-{gamma}1b for idiopathic pulmonary fibrosis. Chest 127(1):171-177
20. Travis WD, Hunninghake G, King TE Jr, Lynch DA, Colby TV, Galvin JR et al (2008) Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 177(12):1338-1347
21. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH et al (2002) Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 19(2):275-283
22. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr et al (2005) The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142(12 Pt 1):963-967
23. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA et al (2008) BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177(1):75-81
24. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174(7):795-802
25. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in sclero-derma lung disease. N Engl J Med 354(25):2655-2666
26. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962-3970
27. DuBois R, Albera C, Bradford WZ, Costabel U, Hormel P, King Jr TE et al (2009) Predictors of mortality in patients with idio-pathic pulmonary fibrosis. In: American Thoracic Society international conference, San Diego, California
28. Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP 3rd (2004) Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 64(4):405-430
29. Thannickal VJ, Flaherty KR, Martinez FJ, Lynch JP 3rd (2004) Idiopathic pulmonary fibrosis: emerging concepts on pharmaco-therapy. Expert Opin Pharmacother 5(8):1671-1686
30. Brown KK, Raghu G (2004) Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects. Clin Chest Med 25(4):759-772 vii